Evidence map›Paper›PMID 41963524›Full record

ArticleScientific reports2026

Tear fluid as a novel specimen for detection of alpha-synuclein seeding activity in Parkinson's disease.

Matteo Costanzo, Anna Ladogana, Marco Sbriccoli, Francesco Marchet, Flavia Porreca, Clara Salciccia, Michele Equestre, Gabriele Moracci, Maria Ilenia De Bartolo, Giulia Ruocco and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Matteo CostanzoDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Anna LadoganaDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy. Anna.ladogana@iss.it.
Marco SbriccoliDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Francesco MarchetIRCCS Neuromed, Pozzilli, Italy.
Flavia PorrecaDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Clara SalcicciaDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Michele EquestreDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Gabriele MoracciDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Maria Ilenia De BartoloIRCCS Neuromed, Pozzilli, Italy.
Giulia RuoccoDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Filippo Carlo CarlàDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Antonella ConteDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Giovanni FabbriniDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Daniele BelvisiDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Anna PoleggiDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson’s disease (PD) is a clinically heterogeneous neurodegenerative disorder characterized by intraneuronal accumulation of misfolded α-synuclein. Real-time quaking-induced conversion (RT-QuIC) detects seeding-competent αSyn species but commonly relies on invasive matrices. We evaluated tear fluid (TF) as a non-invasive biofluid for αSyn RT-QuIC in 44 PD patients and 32 matched healthy controls (HCs). ROC analyses were performed on participant-level readouts (mean of four technical replicates), and optimal cut-offs were selected using the Youden index before being applied to each technical replicate. At the subject level, the best trade-offs were observed at maximum fluorescence (MaxRFU) ≥ 2/4 (sensitivity 59.1%; specificity 65.6%), MedianRFU ≥ 3/4 (sensitivity 40.9%; specificity 78.1%), and area under fluorescence curve (AUFC) ≥ 3/4 (sensitivity 47.7%; specificity 71.9%). In a sensitivity analysis excluding RT-QuIC positive HCs with potential prodromal/risk features, specificity increased to 75% (MaxRFU), 86.2% (MedianRFU), and 79.3% (AUFC). Assay-characterization analyses, performed including all technical replicates, showed significantly higher fluorescence signals throughout the RT-QuIC amplification curve (p < 0.0001) with shorter lag phase, higher MedianRFU and MaxRFU, and larger AUFC values in PD than in HCs (all p < 0.05). Exploratory subgroup analyses suggested possible phenotype-related variability in test response. Our findings suggest that αSyn seeding activity may be detected in TF. Despite suboptimal sensitivity, non-invasiveness and promising specificity support further optimization of TF-based RT-QuIC as a diagnostic tool for synucleinopathies.

Indexed as

alpha-SynucleinParkinson DiseaseTearsAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedROC CurveSensitivity and Specificityalpha-SynucleinBiomarkers

Identifiers

PMID41963524
PMCPMC13199432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.